CoChat

BCL6 orchestrates Tfh cell differentiation via multiple distinct mechanisms

Open access

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Follicular helper T cells (Tfh cells) are required for T cell help to B cells, and BCL6 is the defining transcription factor of Tfh cells. However, the functions of BCL6 in Tfh cells have largely remained unclear. Here we defined the BCL6 cistrome in primary human germinal center Tfh cells to assess mechanisms of BCL6 regulation of CD4 T cells, comparing and contrasting BCL6 function in T and B cells. BCL6 primarily acts as a repressor in Tfh cells, and BCL6 binding was associated with control of Tfh cell migration and repression of alternative cell fates. Interestingly, although some BCL6-bound genes possessed BCL6 DNA–binding motifs, many BCL6-bound loci were instead characterized by the presence of DNA motifs for AP1 or STAT. AP1 complexes are key positive downstream mediators of TCR signaling and external stimuli. We show that BCL6 can directly bind AP1, and BCL6 depends on AP1 for recruitment to BCL6-binding sites with AP1 motifs, suggesting that BCL6 subverts AP1 activity. These findings reveal that BCL6 has broad and multifaceted effects on Tfh biology and provide insight into how this master regulator mediates distinct cell context–dependent phenotypes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20141380

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. BCL6 binds thousands of Tfh genes involved in T cell–related biological networks. (A) Cell sorting strategy for the isolation of GC Tfh cells and BCL6 staining of individual populations. (B) Pie chart of the genome-wide distribution of BCL6 Tfh peaks based on RefSeq. Peaks occurring within ±2 kb of the TSS and TES were considered promoter and 3′UTR peaks, respectively. (C) Frequency of BCL6 motifs present in BCL6 peaks localized relative to the BCL6 peak summit. (D) Pathway analysis of genes associated with BCL6 peaks using the GO and KEGG databases and curated T cell datasets. Color key indicates p-value enrichment. Data are from two experiments, comprising primary Tfh cells from three human donors.
Figure 1. BCL6 binds thousands of Tfh genes involved in T cell–related biological networks. (A) Cell sorting strategy for the isolation of GC Tfh cells and BCL6 staining of individual populations. (B) Pie chart of the genome-wide distribution of BCL6 Tfh peaks based on RefSeq. Peaks occurring within ±2 kb of the TSS and TES were considered promoter and 3′UTR peaks, respectively. (C) Frequency of BCL6 motifs present in BCL6 peaks localized relative to the BCL6 peak summit. (D) Pathway analysis of genes associated with BCL6 peaks using the GO and KEGG databases and curated T cell datasets. Color key indicates p-value enrichment. Data are from two experiments, comprising primary Tfh cells from three human donors.CC BY-NC-SA · PubMed Central
Figure 2. BCL6 targets Tfh genes mainly involved in T cell signaling, differentiation, and migration pathways to drive the GC Tfh phenotype. (A–E) Graphical representation of BCL6 targeted pathway components involved in T cell receptor signaling (A), Th17 cell differentiation (B), Th2 cell differentiation (C), T reg cell signaling (D), and T cell migration (E). Proteins encoded by genes bound by BCL6 are shown in blue. Data are from two experiments, comprising primary Tfh cells from three human donors.
Figure 2. BCL6 targets Tfh genes mainly involved in T cell signaling, differentiation, and migration pathways to drive the GC Tfh phenotype. (A–E) Graphical representation of BCL6 targeted pathway components involved in T cell receptor signaling (A), Th17 cell differentiation (B), Th2 cell differentiation (C), T reg cell signaling (D), and T cell migration (E). Proteins encoded by genes bound by BCL6 are shown in blue. Data are from two experiments, comprising primary Tfh cells from three human donors.CC BY-NC-SA · PubMed Central
Figure 3. BCL6 most potently represses promoters where it binds to its cognate DNA motif. (A) Normalized read density profiles of all gene promoters in Tfh cells ranked from high to low BCL6 read density for GC Tfh BCL6, H3K4me1, H3K4me3, and H3K27ac ChIP-seq. Promoters with BCL6 peaks containing BCL6 motifs are marked blue. (B) Mean normalized read density profiles of H3K4 methylation marks and BCL6 density surrounding the TSSs in GC Tfh cells. Density values were normalized to the total number of reads. (C) BCL6 flow cytometry staining of T cells transduced with BCL6-LV or control vector (Ctrl-LV). (D) GSEA analysis based on global gene expression changes after BCL6 lentiviral induction in CD4 T cells versus control lentivirus. Up and down indicate the relative gene up- or down-regulation after BCL6 expression. The gene sets used were all Tfh genes with BCL6 promoter binding (left), Tfh genes with BCL6 promoter peaks containing the BCL6 motif (middle), and Tfh genes with high enrichment BCL6 promoter peaks (top 25%) that contained BCL6 motifs (right). FDR is based on 1,000 permutations. (E) Read density tracks of BCL6 ChIP-seq enrichment in selected GC Tfh cell promoters. BCL6 peaks are indicated by a blue box, whereas BCL6 motifs are indicated by a black box (rpm, reads per million). ChIP-seq data are from two experiments, comprising primary CD4 T cells from three human donors. (F) Microarray comparison of BCL6 target gene expression levels for IFNGR1, STAT4, RORA, GATA3, and GIMAP1 in BCL6-LV+ CD4 T cells relative to CD4 T cells transduced with control vector. Data are from six independent donors. (G) Comparison of BCL6 target gene expression levels in CXCR5hi (GC Tfh) versus CXCR5− cells (non-Tfh) calculated by qPCR. Data are from four independent donors and are representative of two independent experiments. Fold changes were normalized to GAPDH and are shown relative to non-Tfh. (F and G) Error bars indicate SEM. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.
Figure 3. BCL6 most potently represses promoters where it binds to its cognate DNA motif. (A) Normalized read density profiles of all gene promoters in Tfh cells ranked from high to low BCL6 read density for GC Tfh BCL6, H3K4me1, H3K4me3, and H3K27ac ChIP-seq. Promoters with BCL6 peaks containing BCL6 motifs are marked blue. (B) Mean normalized read density profiles of H3K4 methylation marks and BCL6 density surrounding the TSSs in GC Tfh cells. Density values were normalized to the total number of reads. (C) BCL6 flow cytometry staining of T cells transduced with BCL6-LV or control vector (Ctrl-LV). (D) GSEA analysis based on global gene expression changes after BCL6 lentiviral induction in CD4 T cells versus control lentivirus. Up and down indicate the relative gene up- or down-regulation after BCL6 expression. The gene sets used were all Tfh genes with BCL6 promoter binding (left), Tfh genes with BCL6 promoter peaks containing the BCL6 motif (middle), and Tfh genes with high enrichment BCL6 promoter peaks (top 25%) that contained BCL6 motifs (right). FDR is based on 1,000 permutations. (E) Read density tracks of BCL6 ChIP-seq enrichment in selected GC Tfh cell promoters. BCL6 peaks are indicated by a blue box, whereas BCL6 motifs are indicated by a black box (rpm, reads per million). ChIP-seq data are from two experiments, comprising primary CD4 T cells from three human donors. (F) Microarray comparison of BCL6 target gene expression levels for IFNGR1, STAT4, RORA, GATA3, and GIMAP1 in BCL6-LV+ CD4 T cells relative to CD4 T cells transduced with control vector. Data are from six independent donors. (G) Comparison of BCL6 target gene expression levels in CXCR5hi (GC Tfh) versus CXCR5− cells (non-Tfh) calculated by qPCR. Data are from four independent donors and are representative of two independent experiments. Fold changes were normalized to GAPDH and are shown relative to non-Tfh. (F and G) Error bars indicate SEM. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.CC BY-NC-SA · PubMed Central
Figure 4. BCL6 binding and gene regulation in Tfh cells differs compared with GC B cells with distinct pattern mainly outside promoters. (A) Overlap of BCL6-binding sites in Tfh (blue) and GC B cells (green). (B) Normalized BCL6 ChIP-seq read densities plotted for Tfh cells (y axis) versus B cells (x axis) for each peak corresponding to peaks common to Tfh and B cells, Tfh-only peaks, and B cell–only peaks. Density values were normalized to the total number of reads (rpm, reads per million). (C) Boxplots comparing BCL6 Tfh and GC B BCL6 ChIP-seq read densities for B cell–only peaks, Tfh-only peaks, and peaks common to Tfh and B cells. Density values were normalized to the total number of reads. (B and C) Input chromatin density was subtracted from each measurement. (D) Pie chart of the genome-wide distribution of BCL6 peaks common in GC B cells and GC Tfh cells based on RefSeq. Peaks occurring within ±2 kb of the TSS and TES were considered promoter and 3′UTR peaks, respectively. (E) BCL6 density tracks of BCL6 and PRDM1 loci that were commonly bound in GC Tfh and GC B cells. Read densities are shown in blue for GC Tfh BCL6 ChIP-seq and green for GC B BCL6 ChIP-seq. (F) Pie chart of the genome-wide distribution of GC B-only BCL6 peaks. (G) BCL6 density tracks of SYK and MSH6 that were bound by BCL6 in GC B cells but not in GC Tfh cells. (H) Pie chart of the genome-wide distribution of Tfh-only BCL6 peaks. (I) BCL6 density tracks the IL21 and PLCG1 loci that were bound by BCL6 in GC Tfh cells but not in GC B cells. (J) Tfh and GCB BCL6 read density on the SELPLG locus where BCL6 binds at different sites. ChIP-seq data are from two experiments, comprising primary CD4 T cells from three human donors. (K) qChIP experiments confirm BCL6 is selectively enriched at the SYK and IL21 loci in GC B and GC Tfh cells, respectively. BCL6 binds the PRDM1 promoter in both B and T cells. Nonspecific IgG antibody was used as a negative immunoprecipitation control. Data for cells from three separate donors are shown, representative of two independent experiments. Values are shown as percentage of input chromatin. The BCL6 intron 9 served as a negative control locus. Error bars indicate SEM.
Figure 4. BCL6 binding and gene regulation in Tfh cells differs compared with GC B cells with distinct pattern mainly outside promoters. (A) Overlap of BCL6-binding sites in Tfh (blue) and GC B cells (green). (B) Normalized BCL6 ChIP-seq read densities plotted for Tfh cells (y axis) versus B cells (x axis) for each peak corresponding to peaks common to Tfh and B cells, Tfh-only peaks, and B cell–only peaks. Density values were normalized to the total number of reads (rpm, reads per million). (C) Boxplots comparing BCL6 Tfh and GC B BCL6 ChIP-seq read densities for B cell–only peaks, Tfh-only peaks, and peaks common to Tfh and B cells. Density values were normalized to the total number of reads. (B and C) Input chromatin density was subtracted from each measurement. (D) Pie chart of the genome-wide distribution of BCL6 peaks common in GC B cells and GC Tfh cells based on RefSeq. Peaks occurring within ±2 kb of the TSS and TES were considered promoter and 3′UTR peaks, respectively. (E) BCL6 density tracks of BCL6 and PRDM1 loci that were commonly bound in GC Tfh and GC B cells. Read densities are shown in blue for GC Tfh BCL6 ChIP-seq and green for GC B BCL6 ChIP-seq. (F) Pie chart of the genome-wide distribution of GC B-only BCL6 peaks. (G) BCL6 density tracks of SYK and MSH6 that were bound by BCL6 in GC B cells but not in GC Tfh cells. (H) Pie chart of the genome-wide distribution of Tfh-only BCL6 peaks. (I) BCL6 density tracks the IL21 and PLCG1 loci that were bound by BCL6 in GC Tfh cells but not in GC B cells. (J) Tfh and GCB BCL6 read density on the SELPLG locus where BCL6 binds at different sites. ChIP-seq data are from two experiments, comprising primary CD4 T cells from three human donors. (K) qChIP experiments confirm BCL6 is selectively enriched at the SYK and IL21 loci in GC B and GC Tfh cells, respectively. BCL6 binds the PRDM1 promoter in both B and T cells. Nonspecific IgG antibody was used as a negative immunoprecipitation control. Data for cells from three separate donors are shown, representative of two independent experiments. Values are shown as percentage of input chromatin. The BCL6 intron 9 served as a negative control locus. Error bars indicate SEM.CC BY-NC-SA · PubMed Central
Figure 5. Comparison of specialized BCL6 GC Tfh and GC B cell targeted chromatin landscape. Heat maps of read density profiles of BCL6, H3K4me1, and H3K27ac ChIP-seq in GC B and Tfh cells surrounding BCL6 peaks outside promoters. Maps were centered at the BCL6 peak summit and were separated in peaks common to GC B and T cells, GC Tfh-only peaks, and GC B-only peaks. T cell ChIP-seq data are from two experiments, comprising primary CD4 T cells from three human donors. Values were normalized to the total number of reads.
Figure 5. Comparison of specialized BCL6 GC Tfh and GC B cell targeted chromatin landscape. Heat maps of read density profiles of BCL6, H3K4me1, and H3K27ac ChIP-seq in GC B and Tfh cells surrounding BCL6 peaks outside promoters. Maps were centered at the BCL6 peak summit and were separated in peaks common to GC B and T cells, GC Tfh-only peaks, and GC B-only peaks. T cell ChIP-seq data are from two experiments, comprising primary CD4 T cells from three human donors. Values were normalized to the total number of reads.CC BY-NC-SA · PubMed Central
Figure 6. BCL6 targets T cell–specific enhancers associated with transcriptional repression and a poised chromatin configuration. (A) BCL6 and H3K4me1 ChIP-seq density profiles derived from GC Tfh cells (blue). Enrichment represents the mean normalized read density in Tfh-only BCL6-bound enhancers. (B) Mean conservation score (placental mammal phastCons) of BCL6-bound enhancers relative to the BCL6 peak summit. Random regions were used as a control. (C) Heat maps representing BCL6, H3K4me1, and H3K27ac normalized read density in GC Tfh-only BCL6 enhancers in GC Tfh cells versus GC B cells. (D) Pie chart representing the proportion of BCL6 GC Tfh enhancer peaks (H3K4me1+) that are enriched (green) or depleted (red) in H3K27ac, which positively correlates with enhancer activity. (E) GSEA analysis of genes associated with “poised” BCL6-bound Tfh enhancers and “poised” BCL6-bound Tfh enhancers that also contained the cognate BCL6 motif. GSEA was performed using gene expression changes induced by BCL6 transduction in CD4 T cells. Up and down indicate the relative gene up- or down-regulation after BCL6 expression. 1,000 permutations were used. (F) Pathway analysis of genes linked to “poised” BCL6 Tfh enhancers using PAGE. Color key indicates enrichment p-values. (G) Read density tracks of BCL6 ChIP-seq enrichment in selected GC Tfh cell enhancers. BCL6 peaks are indicated by a blue box, whereas BCL6 motifs are indicated by a black box. T cell ChIP-seq data are from two experiments, comprising primary CD4 T cells from three human donors. (H) Comparison of BCL6 target gene expression levels in CXCR5+ (GC Tfh) versus CXCR5− cells (non-Tfh) calculated by qPCR. Data are from four independent donors and are representative of two independent experiments. Fold changes were normalized to GAPDH and are shown relative to non-Tfh. Error bars indicate SEM. ***, P < 0.001; ****, P < 0.0001.
Figure 6. BCL6 targets T cell–specific enhancers associated with transcriptional repression and a poised chromatin configuration. (A) BCL6 and H3K4me1 ChIP-seq density profiles derived from GC Tfh cells (blue). Enrichment represents the mean normalized read density in Tfh-only BCL6-bound enhancers. (B) Mean conservation score (placental mammal phastCons) of BCL6-bound enhancers relative to the BCL6 peak summit. Random regions were used as a control. (C) Heat maps representing BCL6, H3K4me1, and H3K27ac normalized read density in GC Tfh-only BCL6 enhancers in GC Tfh cells versus GC B cells. (D) Pie chart representing the proportion of BCL6 GC Tfh enhancer peaks (H3K4me1+) that are enriched (green) or depleted (red) in H3K27ac, which positively correlates with enhancer activity. (E) GSEA analysis of genes associated with “poised” BCL6-bound Tfh enhancers and “poised” BCL6-bound Tfh enhancers that also contained the cognate BCL6 motif. GSEA was performed using gene expression changes induced by BCL6 transduction in CD4 T cells. Up and down indicate the relative gene up- or down-regulation after BCL6 expression. 1,000 permutations were used. (F) Pathway analysis of genes linked to “poised” BCL6 Tfh enhancers using PAGE. Color key indicates enrichment p-values. (G) Read density tracks of BCL6 ChIP-seq enrichment in selected GC Tfh cell enhancers. BCL6 peaks are indicated by a blue box, whereas BCL6 motifs are indicated by a black box. T cell ChIP-seq data are from two experiments, comprising primary CD4 T cells from three human donors. (H) Comparison of BCL6 target gene expression levels in CXCR5+ (GC Tfh) versus CXCR5− cells (non-Tfh) calculated by qPCR. Data are from four independent donors and are representative of two independent experiments. Fold changes were normalized to GAPDH and are shown relative to non-Tfh. Error bars indicate SEM. ***, P < 0.001; ****, P < 0.0001.CC BY-NC-SA · PubMed Central
Figure 7. Enhancer chromatin profiles during Tfh cell differentiation. Mean ChIP-seq density profiles of the H3K4me1 and H3K27ac chromatin marks in CD4 T cells and GC Tfh cells surrounding BCL6 peaks. Plots were centered at the BCL6 peak summit and represent poised Tfh enhancers bound by BCL6. ChIP-seq data are from two experiments, comprising primary CD4 T cells from three human donors. Values were normalized to the total number of reads.
Figure 7. Enhancer chromatin profiles during Tfh cell differentiation. Mean ChIP-seq density profiles of the H3K4me1 and H3K27ac chromatin marks in CD4 T cells and GC Tfh cells surrounding BCL6 peaks. Plots were centered at the BCL6 peak summit and represent poised Tfh enhancers bound by BCL6. ChIP-seq data are from two experiments, comprising primary CD4 T cells from three human donors. Values were normalized to the total number of reads.CC BY-NC-SA · PubMed Central
Figure 8. BCL6-mediated repression of key Tfh target genes is linked to interaction with AP1 and recruitment to AP1 DNA–binding sites. (A) De novo motif analysis of BCL6 GC Tfh peaks using HOMER identified the AP1 and STAT DNA motifs among the most highly enriched in Tfh BCL6 peaks. P-values are indicated. (B) Human GC Tfh BCL6-binding sites identified in this study containing AP1 or STAT motifs that were homologous to sites in the mouse genome were queried for AP1 and STAT binding based on published Th17 ChIP-seq datasets. Bound versus unbound fractions are indicated. (C and D) GSEA analysis based on global gene expression changes after BCL6 lentiviral induction in CD4 T cells versus control lentivirus. Up and down indicate the relative gene up- or down-regulation after BCL6 expression. Data are from six independent replicates. The gene sets tested were as follows: (C) promoters with BCL6 peaks containing STAT motifs (left) and poised enhancers with BCL6 peaks containing STAT motifs (right); (D) promoters with BCL6 peaks containing AP1 motifs (left) and poised enhancers with BCL6 peaks containing AP1 motifs (right). FDR is based on 1,000 permutations. (E) Fraction of BCL6 peaks containing BCL6, AP1, or STAT motifs in peaks with lower, intermediate, or high BCL6 enrichment. (F) BCL6 and AP1 motif containing BCL6-bound peaks are primarily found in separate sets of gene.
Figure 8. BCL6-mediated repression of key Tfh target genes is linked to interaction with AP1 and recruitment to AP1 DNA–binding sites. (A) De novo motif analysis of BCL6 GC Tfh peaks using HOMER identified the AP1 and STAT DNA motifs among the most highly enriched in Tfh BCL6 peaks. P-values are indicated. (B) Human GC Tfh BCL6-binding sites identified in this study containing AP1 or STAT motifs that were homologous to sites in the mouse genome were queried for AP1 and STAT binding based on published Th17 ChIP-seq datasets. Bound versus unbound fractions are indicated. (C and D) GSEA analysis based on global gene expression changes after BCL6 lentiviral induction in CD4 T cells versus control lentivirus. Up and down indicate the relative gene up- or down-regulation after BCL6 expression. Data are from six independent replicates. The gene sets tested were as follows: (C) promoters with BCL6 peaks containing STAT motifs (left) and poised enhancers with BCL6 peaks containing STAT motifs (right); (D) promoters with BCL6 peaks containing AP1 motifs (left) and poised enhancers with BCL6 peaks containing AP1 motifs (right). FDR is based on 1,000 permutations. (E) Fraction of BCL6 peaks containing BCL6, AP1, or STAT motifs in peaks with lower, intermediate, or high BCL6 enrichment. (F) BCL6 and AP1 motif containing BCL6-bound peaks are primarily found in separate sets of gene.CC BY-NC-SA · PubMed Central
Figure 9. BCL6-mediated repression of key Tfh target genes is linked to interaction with AP1 and recruitment to AP1 DNA–binding sites. (A) Immunoblot of BCL6 and AP1 in MCC cells induced to express BCL6 by retroviral transduction and/or PMA/ionomycin stimulation. (B) Coimmunoprecipitation of BCL6 and AP1 in MCC cells induced to express BCL6 by retroviral transduction. (C) Coimmunoprecipitation of BCL6 and AP1 in MCC cells induced to express BCL6 by PMA/ionomycin stimulation. (A–C) TBP was used as a loading control. Nonspecific IgG served as an immunoprecipitation negative control. Data shown are representative of five or more experiments. (D) Read density tracks of BCL6 ChIP-seq enrichment in selected GC Tfh cell promoters. (E) Comparison of PRDM1 and RUNX1 expression levels in CXCR5+ (GC Tfh) versus CXCR5− cells (non-Tfh) calculated by qPCR. (F) GC Tfh BCL6 read density tracks in selected genes with BCL6 peaks at AP1 motif–containing distal and intronic sites. (D and F) BCL6 peaks are indicated in blue and AP1 motifs in red. (G) Comparison of CCR6 and CCR7 expression levels in CXCR5+ (GC Tfh) versus CXCR5− cells (non-Tfh) calculated by qPCR. (E and G) Fold changes were normalized to GAPDH and are shown relative to non-Tfh. (H) BCL6 and AP1 ChIP performed in human GC Tfh cells (CXCR5hiPD1hi) showing enrichment at the PRDM1 promoter containing an AP1 motif and the CCR6 enhancer. Data are from three independent experiments. (I) ChIP-reChIP with AP1 followed by BCL6 performed in human GC Tfh cells (CXCR5hiPD1hi) showing enrichment at the PRDM1 promoter containing an AP1 motif and the CCR6 enhancer. Data shown are three technical replicates from each of two independent donors and are representative of three independent experiments. (H and I) Enrichment was calculated as percentage of input chromatin, and nonspecific IgG antibody was used as a negative immunoprecipitation control. BCL6 intron 9 primers were used as a negative control locus. (J) BCL6 and AP1 ChIP performed in Bcl6-RV+ MCC cells with and without shRNAmir for cJun showing decreased BCL6 enrichment at the PRDM1 promoter and the STAT3 enhancer in treated cells. Enrichment was calculated as percentage of input chromatin, and nonspecific IgG antibody was used as a negative immunoprecipitation control. BCL6 promoter region containing BCL6-binding motif and no AP1 motif was used as a positive control for BCL6 enrichment, and BCL6 intron 9 primers were used as a negative control locus. Data shown are four technical replicates and are representative of three independent experiments. (E and G–J) Error bars indicate SEM. *, P <0.05; ***, P < 0.001; ****, P < 0.0001.
Figure 9. BCL6-mediated repression of key Tfh target genes is linked to interaction with AP1 and recruitment to AP1 DNA–binding sites. (A) Immunoblot of BCL6 and AP1 in MCC cells induced to express BCL6 by retroviral transduction and/or PMA/ionomycin stimulation. (B) Coimmunoprecipitation of BCL6 and AP1 in MCC cells induced to express BCL6 by retroviral transduction. (C) Coimmunoprecipitation of BCL6 and AP1 in MCC cells induced to express BCL6 by PMA/ionomycin stimulation. (A–C) TBP was used as a loading control. Nonspecific IgG served as an immunoprecipitation negative control. Data shown are representative of five or more experiments. (D) Read density tracks of BCL6 ChIP-seq enrichment in selected GC Tfh cell promoters. (E) Comparison of PRDM1 and RUNX1 expression levels in CXCR5+ (GC Tfh) versus CXCR5− cells (non-Tfh) calculated by qPCR. (F) GC Tfh BCL6 read density tracks in selected genes with BCL6 peaks at AP1 motif–containing distal and intronic sites. (D and F) BCL6 peaks are indicated in blue and AP1 motifs in red. (G) Comparison of CCR6 and CCR7 expression levels in CXCR5+ (GC Tfh) versus CXCR5− cells (non-Tfh) calculated by qPCR. (E and G) Fold changes were normalized to GAPDH and are shown relative to non-Tfh. (H) BCL6 and AP1 ChIP performed in human GC Tfh cells (CXCR5hiPD1hi) showing enrichment at the PRDM1 promoter containing an AP1 motif and the CCR6 enhancer. Data are from three independent experiments. (I) ChIP-reChIP with AP1 followed by BCL6 performed in human GC Tfh cells (CXCR5hiPD1hi) showing enrichment at the PRDM1 promoter containing an AP1 motif and the CCR6 enhancer. Data shown are three technical replicates from each of two independent donors and are representative of three independent experiments. (H and I) Enrichment was calculated as percentage of input chromatin, and nonspecific IgG antibody was used as a negative immunoprecipitation control. BCL6 intron 9 primers were used as a negative control locus. (J) BCL6 and AP1 ChIP performed in Bcl6-RV+ MCC cells with and without shRNAmir for cJun showing decreased BCL6 enrichment at the PRDM1 promoter and the STAT3 enhancer in treated cells. Enrichment was calculated as percentage of input chromatin, and nonspecific IgG antibody was used as a negative immunoprecipitation control. BCL6 promoter region containing BCL6-binding motif and no AP1 motif was used as a positive control for BCL6 enrichment, and BCL6 intron 9 primers were used as a negative control locus. Data shown are four technical replicates and are representative of three independent experiments. (E and G–J) Error bars indicate SEM. *, P <0.05; ***, P < 0.001; ****, P < 0.0001.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

Metadata

Authors
Hatzi, K., Nance, J. P., Kroenke, M. A., Bothwell, M., Haddad, E. K., Melnick, A., & Crotty, S.
Affiliations
  • Cornell University (US)
  • La Jolla Institute for Immunology (US)
  • University of California San Diego (US)
  • Vaccine & Gene Therapy Institute of Florida (US)
Corresponding author
  • Melnick, Ari
  • Crotty, Shane
Venue
Journal of Experimental Medicine
Published
2015-03-30
Volume
212
Issue
4
Pages
539-553
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2113398790
Cited by
261
References
47
Citations by year
2026: 12 · 2025: 17 · 2024: 18 · 2023: 18 · 2022: 27 · 2021: 29 · 2020: 28 · 2019: 29 · 2018: 24 · 2017: 25 · 2016: 25 · 2015: 9
FWCI
13.64
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Funders
  • U.S. Public Health Service (R01 104348)
  • National Institute of Allergy and Infectious Diseases (R01AI072543, AI109976, U19AI109976, R01AI106482, UM1AI100663)
  • National Center for Research Resources (S10RR027366)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Keywords
BCL6, T follicular helper cells, germinal center, transcriptional repression, AP-1, STAT, T cell receptor signaling, T cell differentiation, T cell help to B cells
MeSH terms
B-Lymphocytes, Binding Sites, Cell Differentiation, DNA-Binding Proteins, Female, T-Lymphocytes, Helper-Inducer, Humans, Male, Transcription Factor AP-1, Amino Acid Motifs, STAT Transcription Factors, Proto-Oncogene Proteins c-bcl-6

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.